




RealRate

PHARMACEUTICAL 2020

Statera Biopharma Inc
Rank 319 of 363



The relative strengths and weaknesses of Statera Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 7.5% points. The greatest weakness of Statera Biopharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 128%, being 110% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	2,003
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,521
Liabilities, Non-Current	0
Other Assets	19
Other Compr. Net Income	91
Other Expenses	0
Other Liabilities	0
Other Net Income	-611
Other Revenues	922
Property and Equipment	16
Research and Development	1,656
Selling, General and Administrative Expense	1,818

Output Variable	Value in 1000 USD
Assets	2,037
Liabilities	1,521
Expenses	3,474
Revenues	922
Stockholders Equity	516
Net Income	-3,163
Comprehensive Net Income	-3,117
BaseVar	4,328
ECR before LimitedLiability	-112%
Economic Capital Ratio	128%